|
Gene: KLB |
Gene summary for KLB |
Gene summary. |
Gene information | Species | Human | Gene symbol | KLB | Gene ID | 152831 |
Gene name | klotho beta | |
Gene Alias | BKL | |
Cytomap | 4p14 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B4DYH5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
152831 | KLB | S43 | Human | Liver | Cirrhotic | 4.06e-02 | -6.65e-02 | -0.0187 |
152831 | KLB | HCC1_Meng | Human | Liver | HCC | 4.26e-48 | 1.30e-01 | 0.0246 |
152831 | KLB | HCC1 | Human | Liver | HCC | 3.94e-22 | 4.25e+00 | 0.5336 |
152831 | KLB | HCC2 | Human | Liver | HCC | 1.73e-22 | 3.42e+00 | 0.5341 |
152831 | KLB | HCC5 | Human | Liver | HCC | 7.53e-06 | 1.01e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | |
Lung | IAC | |
Lung | AIS | |
Lung | AAH | |
Lung | MIAC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0471414 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0471415 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KLB | SNV | Missense_Mutation | novel | c.1535N>T | p.Glu512Val | p.E512V | Q86Z14 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
KLB | SNV | Missense_Mutation | rs745937646 | c.1541C>T | p.Thr514Met | p.T514M | Q86Z14 | protein_coding | tolerated(0.08) | possibly_damaging(0.548) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KLB | SNV | Missense_Mutation | rs758019530 | c.1511N>A | p.Arg504Gln | p.R504Q | Q86Z14 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
KLB | SNV | Missense_Mutation | rs866709953 | c.1270C>T | p.Arg424Cys | p.R424C | Q86Z14 | protein_coding | tolerated(0.19) | possibly_damaging(0.471) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
KLB | SNV | Missense_Mutation | c.1164G>T | p.Met388Ile | p.M388I | Q86Z14 | protein_coding | deleterious(0.03) | benign(0.037) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
KLB | insertion | Frame_Shift_Ins | novel | c.435_436insCCACACGCTATAGGAATACAATGTCCAACGGGGGATT | p.Val146ProfsTer52 | p.V146Pfs*52 | Q86Z14 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
KLB | insertion | In_Frame_Ins | novel | c.700_701insTAGAGA | p.Val233_Lys234insIleGlu | p.V233_K234insIE | Q86Z14 | protein_coding | TCGA-A8-A08C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
KLB | insertion | In_Frame_Ins | novel | c.1288_1289insTCTTCTTATGTAGAGGAGGAAACCCTACACACTACC | p.Thr430delinsIlePheLeuCysArgGlyGlyAsnProThrHisTyrPro | p.T430delinsIFLCRGGNPTHYP | Q86Z14 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
KLB | insertion | In_Frame_Ins | novel | c.1960_1961insACCTTCCCAGAGTCA | p.Pro654delinsHisLeuProArgValThr | p.P654delinsHLPRVT | Q86Z14 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
KLB | insertion | Frame_Shift_Ins | novel | c.1536_1537insGCAATTACTATCA | p.Ser513AlafsTer16 | p.S513Afs*16 | Q86Z14 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
152831 | KLB | ENZYME | NGM313 | |||
152831 | KLB | ENZYME | ethanol | ALCOHOL |
Page: 1 |